SHOC2

Across TCGA pan-cancer cohorts, SHOC2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SHOC2 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SHOC2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SHOC2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

LSCC, HNSC, and PDAC are the cancer types where SHOC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	III,IV	0.400	0.863	.002	21	view →
HNSC	DFS	Tertile	III,IV	1.000	0.904	.038	8	view →
PDAC	OS	Tertile	All	0.491	0.249	.025	5	view →
OV	DFS	Median	All	0.848	1.000	.021	4	view →
CCRCC	OS	Median	All	0.903	1.000	.013	4	view →
LUAD	DFS	Quartile	All	0.711	0.406	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SHOC2–LSCC (DFS)

Open the LSCC breakdown →